Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Edgewise Therapeutics (EWTX)
NASDAQ:EWTX
RESEARCH TOOLSreports
Holding EWTX?
Track your performance easily
EWTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$5.12 - $36.66
Previous Close$33.57
Volume445.47K
Average Volume (3M)1.15M
Market Cap
$3.15B
Enterprise Value$2.64B
Total Cash (Recent Filing)$511.75M
Total Debt (Recent Filing)$4.99M
Price to Earnings (P/E)―
Beta1.92
Next Earnings
Nov 07, 2024EPS Estimate
-$0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.53
Shares Outstanding93,772,288
10 Day Avg. Volume681,081
30 Day Avg. Volume1,154,574
Standard Deviation0.22
R-Squared0.00196
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)5.89
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-27.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-27.70
Forecast
1Y Price Target
$39.40Price Target Upside15.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Edgewise Therapeutics News
Bulls Say, Bears Say
Bulls Say
Drug Efficacy And Market PositionEDG-7500 demonstrates a 67% mean reduction in resting LVOT gradient in patients with obstructive hypertrophic cardiomyopathy, clearly differentiating it from existing cardiac myosin inhibitors.
Regulatory Approval PotentialEWTX anticipates a discussion with the FDA for potential accelerated approval of its treatment for Becker muscular dystrophy if the Phase 2 CANYON study results are successful.
Safety And TolerabilityEDG-7500 is well tolerated across a wide range of doses in healthy volunteers, showing no significant changes in left ventricular ejection fraction, which suggests a favorable safety profile.
Bears Say
Market ReactionAfter EWTX participated in a competitor's event, the stock experienced a significant drop of about 17% due to market speculation.
Project DelaysEWTX has delayed their DMD readout to the fourth quarter of 2024, causing investors to focus on other projects.
Study ChallengesIf EWTX fails to meet the target in the CANYON study, the company will need to revise the study design.
---
Ownership Overview
32.01% Insiders
11.94% Mutual Funds
6.19% Other Institutional Investors
40.48% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
EWTX FAQ
What was Edgewise Therapeutics’s price range in the past 12 months?
Edgewise Therapeutics lowest stock price was $5.12 and its highest was $36.66 in the past 12 months.
What is Edgewise Therapeutics’s market cap?
Currently, no data Available
When is Edgewise Therapeutics’s upcoming earnings report date?
Edgewise Therapeutics’s upcoming earnings report date is Nov 07, 2024 which is in 5 days.
How were Edgewise Therapeutics’s earnings last quarter?
Edgewise Therapeutics released its earnings results on Aug 08, 2024. The company reported -$0.34 earnings per share for the quarter, beating the consensus estimate of -$0.345 by $0.005.
Is Edgewise Therapeutics overvalued?
According to Wall Street analysts Edgewise Therapeutics’s price is currently Undervalued.
Does Edgewise Therapeutics pay dividends?
Edgewise Therapeutics does not currently pay dividends.
What is Edgewise Therapeutics’s EPS estimate?
Edgewise Therapeutics’s EPS estimate is -$0.37.
How many shares outstanding does Edgewise Therapeutics have?
Edgewise Therapeutics has 93,772,285 shares outstanding.
What happened to Edgewise Therapeutics’s price movement after its last earnings report?
Edgewise Therapeutics reported an EPS of -$0.34 in its last earnings report, beating expectations of -$0.345. Following the earnings report the stock price went up 1.952%.
Which hedge fund is a major shareholder of Edgewise Therapeutics?
Among the largest hedge funds holding Edgewise Therapeutics’s share is RA Capital Management. It holds Edgewise Therapeutics’s shares valued at 160M.
---
Edgewise Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$39.40 (15.88% Upside)
$39.40 (15.88% Upside)
Blogger Sentiment
Bullish
EWTX Sentiment 75%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 2.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $8.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 1.6%
Last 30 Days ▼ 1.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
424.53%
12-Months-Change
Fundamentals
Return on Equity
-28.20%
Trailing 12-Months
Asset Growth
60.80%
Trailing 12-Months
Company Description
Edgewise Therapeutics
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases.
---
EWTX Stock 12 Month Forecast
Average Price Target
$39.40
▲(15.88% Upside)
Technical Analysis
Best Analysts Covering EWTX
1 Year
1 Year Success Rate
15/20 ratings generated profit
1 Year Average Return
+84.80%
assigned a buy rating last month
Copying Leonid Timashev's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +84.80% per trade.
---